These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24324104)

  • 1. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
    Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
    Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Ravn J; Sørensen JB
    Eur J Cancer; 2013 Jul; 49(11):2494-503. PubMed ID: 23639410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
    Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
    J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
    Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
    Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer.
    Fischer JR; Manegold C; Bülzebruck H; Vogt-Moykopf I; Drings P
    Semin Oncol; 1994 Jun; 21(3 Suppl 4):20-7. PubMed ID: 7516094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery.
    Yokomise H; Liu D; Chang S; Go T; Ishikawa S; Misaki N; Nakashima N
    Anticancer Res; 2013 Mar; 33(3):1107-15. PubMed ID: 23482788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.
    De Pas T; Pelosi G; de Braud F; Veronesi G; Curigliano G; Leon ME; Danesi R; Noberasco C; d'Aiuto M; Catalano G; Viale G; Spaggiari L
    J Clin Oncol; 2004 Dec; 22(24):4966-70. PubMed ID: 15611511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
    Wirth LJ; Lucca J; Ostler P; Fidias P; Lynch C; Jänne PA; Herbst RS; Johnson BE; Sugarbaker DJ; Mathisen DJ; Lukanich JM; Choi NC; Berman SM; Skarin AT
    Clin Cancer Res; 2003 May; 9(5):1698-704. PubMed ID: 12738723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.